References

  1. TheraSphere™ Yttrium-90 Glass Microspheres – Instructions for Use – English, #990252. SPE Rev. 7. Biocompatibles UK Ltd, a BTG International group company.  http://therasphere.com/physicians-package-insert/TheraSphere_IFU_EU_English_Rev7.pdf.
  2. Package Insert – TheraSphere® Yttrium-90 Glass Microspheres – Rev. 12. Biocompatibles UK Ltd, a BTG International group company.  http://www.therasphere.com/physicians-insert/TS_Package-Insert_USA_v12.pdf.
  3. Canadian Package Insert – TheraSphere® Yttrium-90 Glass Microspheres – Rev. 6. Biocompatibles UK Ltd, a BTG International group company.  http://www.therasphere.com/physicians-package-insert/TheraSphere_PI_Canada_Rev5.pdf
  4. Liver cancer.  http://www.cancer.org. Accessed Accessed June 29, 2015.
  5. Eipel C, Abshagen K, Vollmar B. Regulation of hepatic blood flow: the hepatic arterial buffer response revisited. World J Gastroenterol 2010;16(48):6046-6057.
  6. Barrett K, Brooks H, Boitano S, et al. Ganong’s Review of Medical Physiology. 23rd ed: McGraw-Hill; 2012.
  7. Liver cancer. http://www.cancer.ca. Accessed June 29, 2015.
  8. The liver.  http://www.cancerresearchuk.org. Accessed June 29, 2015.
  9. How does the liver work. http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0072577. Accessed June 29, 2015.
  10. Fact Sheets by Cancer. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. Accessed June 29, 2015.
  11. Chowdhury R, Satoskar R. Chapter 2: Surveillance for Hepatocellular Carcinoma. Primary Liver Cancer Surveillance, Diagnosis and Treatment: Humana Press; 2012.
  12. Kulik LM, Carr BI, Mulcahy MF, et al. Safety and efficacy of Y90 radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 2008;47(1):71–81.
  13. What are the risk factors for liver cancer?  http://www.cancer.org. Accessed June 29, 2015.
  14. Risks and causes of liver cancer.  http://www.cancerresearchuk.org. Accessed June 29, 2015.
  15. Wei SJ. All about liver cancer.  http://www.oncolink.org. Accessed June 29, 2015.
  16. Symptoms of liver cancer.  http://www.cancerresearchuk.org. Accessed June 29, 2015.
  17. Liver cancer: symptoms and signs.  http://www.cancer.net. Accessed June 29, 2015.
  18. Liver cancer: diagnosis.  http://www.cancer.net. Accessed June 29, 2015.
  19. Sasson AR, Sigurdson ER. Surgical treatment of liver metastases. Semin Oncol 2002;29(2):107-118.
  20. About liver metastases.  http://www.mskcc.org. Accessed June 29, 2015.
  21. TNM and number stages of bowel cancer.  http://www.cancerresearchuk.org. Accessed June 29, 2015.
  22. How is colorectal cancer staged?  http://www.cancer.org. Accessed June 29, 2015.
  23. Metastatic cancer.  http://www.cancer.ca. Accessed June 29, 2015.
  24. Colorectal Cancer that has spread to the liver.  http://www.hopkinsmedicine.org/liver_tumor_center. Accessed June 29, 2015.
  25. Data on File. mCRC Phase III Protocol TS-102. A Phase III Clinical Trial Evaluating TheraSphere® in Patients with Metastatic Colorectal Carcinoma to the Liver who have Failed First Line Chemotherapy. EPOCH, Version 5.0. March 5, 2014.
  26. BTG International Inc., Biocompatibles UK Ltd, a BTG International group company. Efficacy Evaluation of TheraSphere Following Failed First Line Chemotherapy in Metastatic Colorectal Cancer (EPOCH). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000–2014; https://clinicaltrials.gov/ct2/show/NCT01483027.
  27. Data on File. Phase III Protocol TS-103. A Phase III Clinical Trial of Intra-arterial TheraSphere® in the Treatment of Patients with Unresectable Hepatocellular Carcinoma (HCC). STOP-HCC, Verison 3.0. September 6, 2013.
  28. BTG International Inc., Biocompatibles UK Ltd, a BTG International group company. Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer (STOP-HCC). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000–2013; https://clinicaltrials.gov/ct2/show/NCT01556490.
  29. Data on File. Phase III Protocol TS-104. A prospective randomized clinical trial on 90Yttrium trans-arterial radio-Embolization (TheraSphere®) vs. Standard of care (sorafenib) for the treatment of advanced Hepatocellular Carcinoma (HCC) with Portal Vein Thrombosis (PVT). YES-P, Version 3.0. August 8, 2014.
  30. BTG International Inc., Biocompatibles UK Ltd, a BTG International group company. Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein (YES-P). In: ClinicalTrials.gov. [Internet]. Bethesda (MD): National Library of Medicine (US). 2000–2014; https://clinicaltrials.gov/ct2/show/NCT01887717.
  31. USA TheraSphere® Reference Manual (PCCS 550A).
  32. Salem R, Thurston KG. Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: Technical and methodologic considerations. J Vasc Interv Radiol 2006;17(8):1251-1278.
  33. Salem R, Lewandowski RJ, Sato KT, et al. Technical aspects of radioembolization with 90Y microspheres. Tech Vasc Interv Radiol 2007;10(1):12-29.
  34. Hilgard P, Hamami M, Fouly AE, et al. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology 2010;52(5):1741-1749.
  35. Mazzaferro V, Sposito C, Bhoori S, et al. Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study. Hepatology 2013;57(5):1826-1837.
  36. Riaz A, Gates VL, Atassi B, et al. Radiation segmentectomy: a novel approach to increase safety and efficacy of radioembolization. Int J Radiat Oncol Biol Phys 2011;79(1):163-171.
  37. Lewandowski RJ, Kulik LM, Riaz A, et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant 2009;9(8):1920-1928.
  38. Salem R, Lewandowski RJ, Kulik L, et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 2011;140(2):497-507 e492.
  39. Kennedy A, Nag S, Salem R, et al. Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys 2007;68(1):13-23.
  40. Merkel C, Montagnese S, Amodio P. Chapter 1: Functional Anatomy of Liver Circulation. In: Keiding S, Sørensen M, eds. Functional Molecular Imaging In Hepatology: Bentham Science; 2012.
  41. Pellerin O, Lin M, Bhagat N, et al. Can C-arm cone-beam CT detect a micro-embolic effect after TheraSphere radioembolization of neuroendocrine and carcinoid liver metastasis? Cancer biotherapy & radiopharmaceuticals 2013;28(6):459-465.
  42. McCann JW, Larkin AM, Martino LJ, et al. Radiation emission from patients treated with selective hepatic radioembolization using yttrium-90 microspheres: are contact restrictions necessary? J Vasc Interv Radiol 2012;23(5):661-667.